GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hologic Inc (NAS:HOLX) » Definitions » Return-on-Tangible-Equity

Hologic (Hologic) Return-on-Tangible-Equity : 144.77% (As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Hologic Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Hologic's annualized net income for the quarter that ended in Dec. 2023 was $986 Mil. Hologic's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $681 Mil. Therefore, Hologic's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 144.77%.

The historical rank and industry rank for Hologic's Return-on-Tangible-Equity or its related term are showing as below:

HOLX' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 70.46   Med: 75.62   Max: 75.62
Current: 70.46

During the past 13 years, Hologic's highest Return-on-Tangible-Equity was 75.62%. The lowest was 70.46%. And the median was 75.62%.

HOLX's Return-on-Tangible-Equity is ranked better than
94.26% of 767 companies
in the Medical Devices & Instruments industry
Industry Median: 1.97 vs HOLX: 70.46

Hologic Return-on-Tangible-Equity Historical Data

The historical data trend for Hologic's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hologic Return-on-Tangible-Equity Chart

Hologic Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity 75.62

Hologic Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 165.37 129.56 -18.56 40.48 144.77

Competitive Comparison of Hologic's Return-on-Tangible-Equity

For the Medical Instruments & Supplies subindustry, Hologic's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hologic's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Hologic's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Hologic's Return-on-Tangible-Equity falls into.



Hologic Return-on-Tangible-Equity Calculation

Hologic's annualized Return-on-Tangible-Equity for the fiscal year that ended in Sep. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=456/( (359.1+847 )/ 2 )
=456/603.05
=75.62 %

Hologic's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=986/( (847+515.2)/ 2 )
=986/681.1
=144.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Hologic  (NAS:HOLX) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Hologic Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Hologic's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Hologic (Hologic) Business Description

Traded in Other Exchanges
Address
250 Campus Drive, Marlborough, MA, USA, 01752
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Executives
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Scott T Garrett director 35 CROSBY DRIVE, BEDFORD MA 01730
Stephen P Macmillan director, officer: President and CEO 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Essex D Mitchell officer: Div. President, GYN Surgical 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Nanaz Mohtashami director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jennifer M Schneiders officer: President, Diag. Solutions 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Benjamin Jordan Cohn officer: Principal Accounting Officer 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Stacey D. Stewart director 5920 WALHONDING ROAD, BETHESDA MD 20816
Elisabeth A Hellmann officer: SVP, Human Resources 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kevin R Thornal officer: Div. President, Diagnostics 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
John M. Griffin officer: General Counsel 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Karleen Marie Oberton officer: Corp. VP, Finance & Acconting 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Erik S Anderson officer: Div. Pres., Breast & Skeletal 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jan Verstreken officer: Group President, International 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Allison P Bebo officer: SVP, Human Resources 250 CAMPUS DRIVE, MARLBOROUGH MA 01752

Hologic (Hologic) Headlines

From GuruFocus

Hologic Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Hologic Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2022 Hologic Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Hologic Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Q4 2023 Hologic Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Hologic Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Hologic Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2021 Hologic Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024